Clinical Trial Update: Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

A completed Phase 2 clinical trial evaluated thalidomide as an anti-angiogenesis therapy in patients with Waldenström macroglobulinemia. The study was sponsored…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Thalomid (thalidomide)

Snippet

Sponsor: University of Arkansas | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: COMPLETED